Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

OXYCODONE HCL & ACETYLSALICYLIC ACID

1 general benefit · 1 not a benefit

Other products in the same Health Canada class (N02A, N02AJ) — coverage varies; not interchangeable

  • Acetaminophen + caffeine + codeine (Teva-Lenoltec No.2): general benefit, Not a benefit
  • Acetaminophen + codeine (PMS-Acetaminophen With Codeine): general benefit, Not a benefit
  • Acetaminophen + oxycodone (Teva-Oxycocet): general benefit, Not a benefit
  • Acetaminophen + tramadol (Tramacet): not a benefit
  • Hydromorphone (Hydromorph Contin): general benefit, Not a benefit
  • Morphine (M-Eslon): general benefit, Not a benefit

4 more in the class list below

Ratio-Oxycodan · DIN 00608157 · 5mg & 325mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ratio-Oxycodan · DIN 00608157 Manufacturer: Ratiopharm Inc.; listing date 1996-10-01 Health Canada: Marketed since 2017-12-21 · brand TEVA-OXYCODAN · ATC N02AJ18 OXYCODONE AND ACETYLSALICYLIC ACID, N02AJ18 OXYCODONE AND ACETYLSALICYLIC ACID · form Tablet · route Oral · ingredients OXYCODONE HYDROCHLORIDE 5 MG, ACETYLSALICYLIC ACID 325 MG · company Teva canada limited · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Ratio-Oxycodan: Formulary list price $0.4599/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4599 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5777 · Verify on the e-Formulary ↗ (DIN 00608157)

Source record
DIN 00608157: Ratio-Oxycodan Raw flags: sec3=Y Item: 280808065; group id 411; item number 1013; lccId None; manufacturer id RPH Source form: Tab; strength: 5mg & 325mg Recorded listing: General benefit Source prices (unrounded): $0.4599; ministry $0.4599 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00608157 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5777
Interchangeable products
Percodan · DIN 01916572 · not recorded
Shortage status: resolved shortage (ended 2026-02-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00608157
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Percodan · DIN 01916572 · 5mg & 325mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2009-06-26 — choose a marketed DIN from the same-category list.Discontinued 2009-06-26 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2009-06-26 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2009-06-26 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Percodan · DIN 01916572 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 2008-12-23 Health Canada: Cancelled post market since 2009-06-26 · brand PERCODAN · ATC N02AJ18 OXYCODONE AND ACETYLSALICYLIC ACID, N02AJ18 OXYCODONE AND ACETYLSALICYLIC ACID · form Tablet · route Oral · ingredients ACETYLSALICYLIC ACID 325 MG, OXYCODONE HYDROCHLORIDE 5 MG · company Bristol-myers squibb canada · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Percodan: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15513 · Verify on the e-Formulary ↗ (DIN 01916572)

Source record
DIN 01916572: Percodan Raw flags: notABenefit=Y, sec3=Y Item: 280808065; group id 411; item number 1013; lccId None; manufacturer id BQU Source form: Tab; strength: 5mg & 325mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01916572 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15513
Interchangeable products
Ratio-Oxycodan · DIN 00608157 · $0.4599
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01916572
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2009-06-26 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:08:08 Opiate Agonists) and how they are covered

Matched class: 28:08:08 Opiate Agonists

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE, ACETAMINOPHEN & CODEINE PHOSPHATE, CODEINE PHOSPHATE, HYDROMORPHONE HCL, METHADONE HCL, MORPHINE SULFATE, OXYCODONE HCL & ACETAMINOPHEN 28:08:08 Opiate Agonists

ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 300mg & 15mg & 15mg, 300mg & 15mg & 30mg · Tab

ACETAMINOPHEN & CODEINE PHOSPHATE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 160mg & 8mg/5mL, 300mg & 30mg, 300mg & 60mg · O/L, Tab

OXYCODONE HCL & ACETAMINOPHEN

· 5 products · General benefit (4), Listed, not a benefit (1) · strengths: 5mg & 325mg · Tab

TRAMADOL HCL & ACETAMINOPHEN

· 11 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 37.5mg & 325mg · Tab

HYDROMORPHONE HCL

· 28 products · General benefit (21), Listed, not a benefit (3), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4) · strengths: 4.5mg, 9mg, 3mg, 6mg, 12mg, 18mg, 2mg/mL, 10mg/mL, 1mg/mL, 1mg, 2mg, 4mg, 8mg · CR Cap, Inj Sol-1mL Pk, Oral Sol, Tab

MORPHINE SULFATE

· 35 products · General benefit (31), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 10mg, 15mg, 30mg, 60mg, 100mg, 2mg/mL, 10mg/mL, 15mg/mL, 50mg/mL, 20mg, 50mg, 200mg, 5mg · ER Cap, Inj Sol Amp, Inj Sol-1mL Pk, SR Cap, SR Tab, Tab

FENTANYL TRANSDERMAL SYSTEM

· 22 products · Listed, not a benefit (6), Limited Use, codes 511 (6), Limited Use, codes 689 (2), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 12mcg/hr, 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr · Trans Patch

ACETYLSALICYLIC ACID & BUTALBITAL & CAFFEINE & CODEINE PHOSPHATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 330mg & 50mg & 40mg & 15mg, 330mg & 50mg & 40mg & 30mg · Cap

OXYCODONE HCL

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg, 20mg · Tab

TRAMADOL HCL

· 13 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 200mg, 300mg, 50mg · ER Tab, Tab

CODEINE PHOSPHATE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 15mg, 30mg · Tab

METHADONE HCL

· 16 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg/mL, 1mg, 5mg, 10mg, 25mg · Oral Concentrate, Oral Concentrate (Cherry Flavour), Oral Concentrate (Unflavoured), Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:08:08 and 2 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: moderately pain
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. OXYCODONE HCL & ACETAMINOPHEN · General benefit (4), Listed, not a benefit (1) INDICATIONS AND CLINICAL USE Adults TEVA-OXYCOCET (oxycodone hydrochloride and acetaminophen) is indicated for the relief of moderate to moderately severe pain, including conditions accompanied by fever. PM: https://pdf.hres.ca/dpd_pm/00047061.PDF; date August 22, 2018; DIN 00608165; fetched 2026-09-10 Product monograph TRAMADOL HCL & ACETAMINOPHEN · Off-Formulary Interchangeable, not an ODB benefit INDICATIONS AND CLINICAL USE Adults: APO-TRAMADOL/ACET (tramadol hydrochloride and acetaminophen) is indicated for the management of moderate to moderately severe pain. PM: https://pdf.hres.ca/dpd_pm/00067347.PDF; date September 14, 2022; DIN 02336790; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS Adults TEVA-OXYCODAN (oxycodone hydrochloride and acetylsalicylic acid (ASA)) is indicated for: • the relief of mild to moderately severe pain, including conditions accompanied by fever and/or inflammation. TEVA-OXYCODAN is not indicated as an as-needed (prn) analgesic. 1.1 Pediatrics (< 18 years of age) The safety and efficacy of TEVA-OXYCODAN has not been studied in the pediatric population. Therefore Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics (> 65 years of age) In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, concomitant disease or other drug therapy (see 10 CLINICAL, Special Populations and Conditions, Geriatrics). https://pdf.hres.ca/dpd_pm/00075881.PDF PM date: May 22, 2024 Source product: TEVA-OXYCODAN; DIN 00608157; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Percodan: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026